Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2018-12-03
2019-06-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections
NCT03406689
Pain Reduction With Topical Bromfenac Versus Artificial Tear After Intravitreal Injection.
NCT06130384
Control of Pain in Intravitreal Injections Using Topical NSAIDs
NCT04343222
Comparison of Acular LS Versus Nevanac for Pain Control in Eyes Undergoing PRK
NCT00347204
Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections
NCT02821390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study participants will then complete the Visual Analog Scale immediately following injection and then after 1 hour, and, 24 hours. The VAS data along with relevant data related to each subject's injection will also be compiled, including, but not limited to: drug injected, diagnosis, co-morbid conditions, history of previous injections, visual acuity, age, and gender.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A single drop of nepafenac 0.3% suspension
A single drop of nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
NSAID
Patching
A light pressure patch applied for two hours
patching
no drug/ patching
A single drop of preservative-free Artificial Tears
A single drop of preservative-free Theratears tear drop, (Akron, Ann Arbor, MI).
Theratears tear drop, (Akron, Ann 111 Arbor, MI)
preservative-free Artificial Tears
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
NSAID
Theratears tear drop, (Akron, Ann 111 Arbor, MI)
preservative-free Artificial Tears
patching
no drug/ patching
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Already scheduled for anti-VEGF injection based on standard of care for disease process.
* Ability to provide written informed consent
* Capable of complying with study protocol.
* Volunteer written informed consent with the understanding that consent may be withdrawn by the subject at any time without prejudice to future care
Exclusion Criteria
* Experiencing baseline eye pain
* Monocular; non-study eye with VA\<20/100.
* Unwilling or unable to follow or comply with all study related procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The New York Eye & Ear Infirmary
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ronald Gentile, MD
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
New York Eye and Ear Infirmary
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
16.15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.